Summary
Global Markets Direct’s, ‘Depression - Pipeline Review, H1 2016’, provides an overview of the Depression pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Depression
- The report reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Depression therapeutics and enlists all their major and minor projects
- The report assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Depression
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Depression
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AB Science SA
Acetylon Pharmaceuticals, Inc.
Ache Laboratorios Farmaceuticos S/A
Adamed Sp. z o.o.
Addex Therapeutics Ltd
Aequus Pharmaceuticals Inc.
Alkermes Plc
Allergan Plc
Alvogen Korea Co., Ltd.
Amorsa Therapeutics Inc.
Anavex Life Sciences Corp.
Angelini Group
Angita B.V.
AstraZeneca Plc
Axsome Therapeutics, Inc.
Azevan Pharmaceuticals, Inc.
BioCrea GmbH
Biogen, Inc.
Bionomics Limited
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Calico LLC
Cerecor Inc.
Clera Inc.
D-Pharm Ltd.
Delpor, Inc.
e-Therapeutics Plc
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
GliaCure Inc.
H. Lundbeck A/S
Heptares Therapeutics Limited
HolsboerMaschmeyer NeuroChemie GmbH
Hua Medicine Ltd.
Hyundai Pharmaceutical Co., Ltd.
Impel NeuroPharma, Inc.
INSYS Therapeutics, Inc.
Intas Pharmaceuticals Ltd.
Intra-Cellular Therapies, Inc.
INVENT Pharmaceuticals, Inc.
Johnson & Johnson
KemPharm, Inc.
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Lixte Biotechnology Holdings, Inc.
Luye Pharma Group Ltd.
M et P Pharma AG
Mapi Pharma Ltd.
Mapreg S.A.S.
Meta-IQ ApS
Methylation Sciences Inc.
MI.TO. Technology S.r.L.
miCure Therapeutics Ltd.
Mitsubishi Tanabe Pharma Corporation
Neuralstem, Inc.
Neurocrine Biosciences, Inc.
NeuroNascent, Inc.
NeurOp, Inc
Newron Pharmaceuticals S.p.A.
Nippon Chemiphar Co., Ltd.
nLife Therapeutics, S.L.
Novartis AG
Omeros Corporation
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Pherin Pharmaceuticals, Inc.
Polleo Pharma Limited
Protagenic Therapeutics Inc.
Reviva Pharmaceuticals Inc.
Richter Gedeon Nyrt.
RTI International
Saniona AB
SK Biopharmaceuticals Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Supernus Pharmaceuticals, Inc.
Suven Life Sciences Ltd.
Taisho Pharmaceutical Holdings Co., Ltd.
Takeda Pharmaceutical Company Limited
Tetra Discovery Partners LLC
Trevena, Inc.
TRImaran Pharma, Inc.
Turing Pharmaceuticals AG
VistaGen Therapeutics , Inc.
Zhejiang Huahai Pharmaceutical Co., Ltd.
Zogenix, Inc.
Zysis Limited
'
Table of Contents
Table of Contents 2
Introduction 7
Depression Overview 8
Therapeutics Development 9
Depression - Therapeutics under Development by Companies 11
Depression - Therapeutics under Investigation by Universities/Institutes 19
Depression - Pipeline Products Glance 21
Depression - Products under Development by Companies 25
Depression - Products under Investigation by Universities/Institutes 36
Depression - Companies Involved in Therapeutics Development 38
Depression - Therapeutics Assessment 126
Drug Profiles 144
Depression - Recent Pipeline Updates 364
Depression - Dormant Projects 448
Depression - Discontinued Products 472
Depression - Product Development Milestones 480
Appendix 489
List of Tables
Number of Products under Development for Depression, H1 2016 27
Number of Products under Development for Depression - Comparative Analysis, H1 2016 28
Number of Products under Development by Companies, H1 2016 30
Number of Products under Development by Companies, H1 2016 (Contd..1) 31
Number of Products under Development by Companies, H1 2016 (Contd..2) 32
Number of Products under Development by Companies, H1 2016 (Contd..3) 33
Number of Products under Development by Companies, H1 2016 (Contd..4) 34
Number of Products under Development by Companies, H1 2016 (Contd..5) 35
Number of Products under Development by Companies, H1 2016 (Contd..6) 36
Number of Products under Investigation by Universities/Institutes, H1 2016 38
Comparative Analysis by Late Stage Development, H1 2016 39
Comparative Analysis by Clinical Stage Development, H1 2016 40
Comparative Analysis by Early Stage Development, H1 2016 41
Comparative Analysis by Unknown Stage Development, H1 2016 42
Products under Development by Companies, H1 2016 43
Products under Development by Companies, H1 2016 (Contd..1) 44
Products under Development by Companies, H1 2016 (Contd..2) 45
Products under Development by Companies, H1 2016 (Contd..3) 46
Products under Development by Companies, H1 2016 (Contd..4) 47
Products under Development by Companies, H1 2016 (Contd..5) 48
Products under Development by Companies, H1 2016 (Contd..6) 49
Products under Development by Companies, H1 2016 (Contd..7) 50
Products under Development by Companies, H1 2016 (Contd..8) 51
Products under Development by Companies, H1 2016 (Contd..9) 52
Products under Development by Companies, H1 2016 (Contd..10) 53
Products under Investigation by Universities/Institutes, H1 2016 54
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 55
Depression - Pipeline by AB Science SA, H1 2016 56
Depression - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 57
Depression - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016 58
Depression - Pipeline by Adamed Sp. z o.o., H1 2016 59
Depression - Pipeline by Addex Therapeutics Ltd, H1 2016 60
Depression - Pipeline by Aequus Pharmaceuticals Inc., H1 2016 61
Depression - Pipeline by Alkermes Plc, H1 2016 62
Depression - Pipeline by Allergan Plc, H1 2016 63
Depression - Pipeline by Alvogen Korea Co., Ltd., H1 2016 64
Depression - Pipeline by Amorsa Therapeutics Inc., H1 2016 65
Depression - Pipeline by Anavex Life Sciences Corp., H1 2016 66
Depression - Pipeline by Angelini Group, H1 2016 67
Depression - Pipeline by Angita B.V., H1 2016 68
Depression - Pipeline by AstraZeneca Plc, H1 2016 69
Depression - Pipeline by Axsome Therapeutics, Inc., H1 2016 70
Depression - Pipeline by Azevan Pharmaceuticals, Inc., H1 2016 71
Depression - Pipeline by BioCrea GmbH, H1 2016 72
Depression - Pipeline by Biogen, Inc., H1 2016 73
Depression - Pipeline by Bionomics Limited, H1 2016 74
Depression - Pipeline by Boehringer Ingelheim GmbH, H1 2016 75
Depression - Pipeline by Bristol-Myers Squibb Company, H1 2016 76
Depression - Pipeline by Calico LLC, H1 2016 77
Depression - Pipeline by Cerecor Inc., H1 2016 78
Depression - Pipeline by Clera Inc., H1 2016 79
Depression - Pipeline by D-Pharm Ltd., H1 2016 80
Depression - Pipeline by Delpor, Inc., H1 2016 81
Depression - Pipeline by e-Therapeutics Plc, H1 2016 82
Depression - Pipeline by Eisai Co., Ltd., H1 2016 83
Depression - Pipeline by Eli Lilly and Company, H1 2016 84
Depression - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 85
Depression - Pipeline by GlaxoSmithKline Plc, H1 2016 86
Depression - Pipeline by GliaCure Inc., H1 2016 87
Depression - Pipeline by H. Lundbeck A/S, H1 2016 88
Depression - Pipeline by Heptares Therapeutics Limited, H1 2016 89
Depression - Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H1 2016 90
Depression - Pipeline by Hua Medicine Ltd., H1 2016 91
Depression - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 92
Depression - Pipeline by Impel NeuroPharma, Inc., H1 2016 93
Depression - Pipeline by INSYS Therapeutics, Inc., H1 2016 94
Depression - Pipeline by Intas Pharmaceuticals Ltd., H1 2016 95
Depression - Pipeline by Intra-Cellular Therapies, Inc., H1 2016 96
Depression - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 97
Depression - Pipeline by Johnson & Johnson, H1 2016 98
Depression - Pipeline by KemPharm, Inc., H1 2016 99
Depression - Pipeline by Lead Discovery Center GmbH, H1 2016 100
Depression - Pipeline by Les Laboratoires Servier SAS, H1 2016 101
Depression - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 102
Depression - Pipeline by Luye Pharma Group Ltd., H1 2016 103
Depression - Pipeline by M et P Pharma AG, H1 2016 104
Depression - Pipeline by Mapi Pharma Ltd., H1 2016 105
Depression - Pipeline by Mapreg S.A.S., H1 2016 106
Depression - Pipeline by Meta-IQ ApS, H1 2016 107
Depression - Pipeline by Methylation Sciences Inc., H1 2016 108
Depression - Pipeline by MI.TO. Technology S.r.L., H1 2016 109
Depression - Pipeline by miCure Therapeutics Ltd., H1 2016 110
Depression - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 111
Depression - Pipeline by Neuralstem, Inc., H1 2016 112
Depression - Pipeline by Neurocrine Biosciences, Inc., H1 2016 113
Depression - Pipeline by NeuroNascent, Inc., H1 2016 114
Depression - Pipeline by NeurOp, Inc, H1 2016 115
Depression - Pipeline by Newron Pharmaceuticals S.p.A., H1 2016 116
Depression - Pipeline by Nippon Chemiphar Co., Ltd., H1 2016 117
Depression - Pipeline by nLife Therapeutics, S.L., H1 2016 118
Depression - Pipeline by Novartis AG, H1 2016 119
Depression - Pipeline by Omeros Corporation, H1 2016 120
Depression - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 121
Depression - Pipeline by Pfizer Inc., H1 2016 122
Depression - Pipeline by Pherin Pharmaceuticals, Inc., H1 2016 123
Depression - Pipeline by Polleo Pharma Limited, H1 2016 124
Depression - Pipeline by Protagenic Therapeutics Inc., H1 2016 125
Depression - Pipeline by Reviva Pharmaceuticals Inc., H1 2016 126
Depression - Pipeline by Richter Gedeon Nyrt., H1 2016 127
Depression - Pipeline by RTI International, H1 2016 128
Depression - Pipeline by Saniona AB, H1 2016 129
Depression - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 130
Depression - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 131
Depression - Pipeline by Supernus Pharmaceuticals, Inc., H1 2016 132
Depression - Pipeline by Suven Life Sciences Ltd., H1 2016 133
Depression - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H1 2016 134
Depression - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 135
Depression - Pipeline by Tetra Discovery Partners LLC, H1 2016 136
Depression - Pipeline by Trevena, Inc., H1 2016 137
Depression - Pipeline by TRImaran Pharma, Inc., H1 2016 138
Depression - Pipeline by Turing Pharmaceuticals AG , H1 2016 139
Depression - Pipeline by VistaGen Therapeutics , Inc., H1 2016 140
Depression - Pipeline by Zhejiang Huahai Pharmaceutical Co., Ltd., H1 2016 141
Depression - Pipeline by Zogenix, Inc., H1 2016 142
Depression - Pipeline by Zysis Limited, H1 2016 143
Assessment by Monotherapy Products, H1 2016 144
Assessment by Combination Products, H1 2016 145
Number of Products by Stage and Target, H1 2016 147
Number of Products by Stage and Mechanism of Action, H1 2016 154
Number of Products by Stage and Route of Administration, H1 2016 159
Number of Products by Stage and Molecule Type, H1 2016 161
Depression Therapeutics - Recent Pipeline Updates, H1 2016 382
Depression - Dormant Projects, H1 2016 466
Depression - Dormant Projects (Contd..1), H1 2016 467
Depression - Dormant Projects (Contd..2), H1 2016 468
Depression - Dormant Projects (Contd..3), H1 2016 469
Depression - Dormant Projects (Contd..4), H1 2016 470
Depression - Dormant Projects (Contd..5), H1 2016 471
Depression - Dormant Projects (Contd..6), H1 2016 472
Depression - Dormant Projects (Contd..7), H1 2016 473
Depression - Dormant Projects (Contd..8), H1 2016 474
Depression - Dormant Projects (Contd..9), H1 2016 475
Depression - Dormant Projects (Contd..10), H1 2016 476
Depression - Dormant Projects (Contd..11), H1 2016 477
Depression - Dormant Projects (Contd..12), H1 2016 478
Depression - Dormant Projects (Contd..13), H1 2016 479
Depression - Dormant Projects (Contd..14), H1 2016 480
Depression - Dormant Projects (Contd..15), H1 2016 481
Depression - Dormant Projects (Contd..16), H1 2016 482
Depression - Dormant Projects (Contd..17), H1 2016 483
Depression - Dormant Projects (Contd..18), H1 2016 484
Depression - Dormant Projects (Contd..19), H1 2016 485
Depression - Dormant Projects (Contd..20), H1 2016 486
Depression - Dormant Projects (Contd..21), H1 2016 487
Depression - Dormant Projects (Contd..22), H1 2016 488
Depression - Dormant Projects (Contd..23), H1 2016 489
Depression - Discontinued Products, H1 2016 490
Depression - Discontinued Products (Contd..1), H1 2016 491
Depression - Discontinued Products (Contd..2), H1 2016 492
Depression - Discontinued Products (Contd..3), H1 2016 493
Depression - Discontinued Products (Contd..4), H1 2016 494
Depression - Discontinued Products (Contd..5), H1 2016 495
Depression - Discontinued Products (Contd..6), H1 2016 496
Depression - Discontinued Products (Contd..7), H1 2016 497
List of Figures
Number of Products under Development for Depression, H1 2016 27
Number of Products under Development for Depression - Comparative Analysis, H1 2016 28
Number of Products under Development by Companies, H1 2016 29
Number of Products under Investigation by Universities/Institutes, H1 2016 37
Comparative Analysis by Late Stage Development, H1 2016 39
Comparative Analysis by Clinical Stage Development, H1 2016 40
Comparative Analysis by Early Stage Products, H1 2016 41
Assessment by Monotherapy Products, H1 2016 144
Assessment by Combination Products, H1 2016 145
Number of Products by Top 10 Targets, H1 2016 146
Number of Products by Stage and Top 10 Targets, H1 2016 146
Number of Products by Top 10 Mechanism of Actions, H1 2016 153
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 153
Number of Products by Top 10 Routes of Administration, H1 2016 158
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 158
Number of Products by Molecule Types, H1 2016 160
Number of Products by Stage and Molecule Types, H1 2016 160
